ANTONIO RAFAEL
ANTELA LOPEZ
Profesor contratado doutor
María del Mar
Masiá Canuto
Publicacións nas que colabora con María del Mar Masiá Canuto (25)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
-
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain
HIV Medicine
2023
-
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Frontiers in Cellular and Infection Microbiology, Vol. 13
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study
AIDS Research and Therapy, Vol. 17, Núm. 1
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
-
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524
2019
-
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
The Lancet, Vol. 393, Núm. 10167, pp. 143-155
-
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
The Lancet, Vol. 393, Núm. 10189, pp. 2428-2438
2018
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Oxidative stress predicts All-Cause mortality in HIV-Infected patients
PLoS ONE, Vol. 11, Núm. 4
-
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: A randomized trial
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 5, pp. 1346-1351
2015
-
Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences
Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095